Bydureon Single Dose Trays to Be Discontinued

The 2mg Single Dose Tray presentation will be permanently discontinued on September 30, 2018
The 2mg Single Dose Tray presentation will be permanently discontinued on September 30, 2018

The Food and Drug Administration (FDA) has issued a discontinuation notice for Bydureon (exenatide extended-release; AstraZeneca) for injectable suspension Single Dose Trays. 

The 2mg Single Dose Tray presentation will be permanently discontinued on September 30, 2018. There are two other delivery options for Bydureon: the Dual Chamber Pen and the BCise autoinjectors.

Related Articles

Bydureon, a glucagon-like peptide-1 (GLP-1) receptor agonist, is currently approved as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes. It works by enhancing glucose-dependent insulin secretion by the pancreatic beta-cell, suppressing inappropriately elevated glucagon secretion, and slowing gastric emptying.

The Dual Chamber Pen is supplied in cartons containing 4 single-dose pens; the BCise is available as cartons containing 4 single-dose autoinjectors.

For more information call (800) 236-9933 or visit FDA.gov.